Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly

Journal of Human Hypertension volume 16, pages S71–S75 (2002)Cite this article

Abstract

Hypertension is an established risk factor for stroke and other cerebrovascular disorders. Both stroke and small lacunar infarcts or white matter lesions can cause cognitive impairment and dementia, and there is evidence that vascular risk factors play a major role in the development of both Alzheimer's disease and vascular dementia. Several large epidemiological studies have shown that raised blood pressure in midlife is a strong risk factor for dementia later in life; however, blood pressure often decreases following the development of dementia. The cognitive function hypothesis proposes that elevated blood pressure increases the risk of decline of cognitive function, and that this can be reversed by active lowering of blood pressure. Evidence in support of this hypothesis comes from the Syst-Eur Dementia project, and from a number of smaller studies. SCOPE (Study on Cognition and Prognosis in the Elderly) is a large prospective study involving almost 5000 elderly patients (age 70–89 years), who are randomised to receive candesartan cilexetil, 8–16 mg, or placebo. Candesartan was chosen for this study because it is effective and well tolerated in elderly patients. SCOPE should provide important information on the long-term effects of AT1-receptor blocker treatment with candesartan on morbidity—including effects on cognitive function—and cardiovascular mortality in elderly hypertensive patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Kannel WB, Gordon T . Evaluation of cardiovascular risk in the elderly: the Framingham Study Bull NY Acad Med 1978 54: 573–591

    CAS  Google Scholar 

  2. Joint National Committee. Sixth National Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) Arch Intern Med 1997 157: 2413–2446

  3. Staessen JA et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials Lancet 2000 355: 865–872

    Article  CAS  Google Scholar 

  4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition, revised American Psychiatric Association: Washington DC 1987

  5. Jorm AF, Korten AE, Henderson AS . The prevalence of dementia: a quantitative integration of the literature Acta Psychiatr Scand 1987 76: 465–479

    Article  CAS  PubMed  Google Scholar 

  6. Tzourio C, Anderson C PROGRESS Management Committee. Blood pressure reduction and risk of dementia inpatients with stroke: rationale of the dementia assessment in PROGRESS (Perindopril Protection against Recurrent Stroke Study). PROGRESS Management Committee J Hypertens 2000 18 (Suppl): S21–24

    Google Scholar 

  7. Hofman A et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study Lancet 1997 349: 151–154

    Article  CAS  PubMed  Google Scholar 

  8. Snowdon DA et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study JAMA 1997 278: 113–114

    Article  Google Scholar 

  9. Elias MF et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study Am J Epidemiol 1993 138: 353–364

    Article  CAS  Google Scholar 

  10. Launer LJ et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study JAMA 1995 274: 1846–1851

    Article  CAS  PubMed  Google Scholar 

  11. Skoog I et al. 15-year longitudinal study of blood pressure and dementia Lancet 1996 347: 1141–1145

    Article  CAS  PubMed  Google Scholar 

  12. Scheinberg P . Dementia due to vascular disease: a multifactorial disorder Stroke 1988 19: 1291–1299

    Article  CAS  PubMed  Google Scholar 

  13. Román GC . Senile dementia of the Binswanger type: a vascular form of dementia in the elderly JAMA 1987 258: 1782–1788

    Article  PubMed  Google Scholar 

  14. Brun A, Englund E . A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study Ann Neurol 1986 19: 253–262

    Article  CAS  PubMed  Google Scholar 

  15. Trenkwalder P et al. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65 years: results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly J Hypertens 1994 12: 709–716

    Article  CAS  PubMed  Google Scholar 

  16. Forette F et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial Lancet 1998 352: 1347–1351

    Article  CAS  PubMed  Google Scholar 

  17. Tedesco MA et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensivepatients Am J Hypertens 1999 12 (11 Pt 1): 1130–1134

    Article  Google Scholar 

  18. Hansson L et al. Study on COgnition and Prognosis in the Elderly (SCOPE) Blood Press 1999 8: 177–183

    Article  CAS  PubMed  Google Scholar 

  19. Hansson L et al. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics Blood Press 2000 9: 146–151

    Article  CAS  PubMed  Google Scholar 

  20. Elmfeldt D, George M, Hüber R, Olofsson B . Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect J Hum Hypertens 1997 11 (Suppl 2): S49–S53

    Google Scholar 

  21. McInnes GT, O'Kane KPJ, Jonker J, Roth J . The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population J Hum Hypertens 1997 11 (Suppl 2): S75–S80

    Google Scholar 

  22. Neldam S, Forsen B for the Multicentre Study Group. Antihypertensive treatment in elderlypatients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide Drugs Aging 2001 18: 225–232

    Article  CAS  PubMed  Google Scholar 

  23. Malmqvist K, Kahan T, Dahl M . Angiotensin II type 1 (AT1) receptor blockade in hypertensive women:benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide Am J Hypertens 2000 13: 504–511

    Article  CAS  PubMed  Google Scholar 

  24. Belcher G et al. Safety and tolerability of candesartan cilexetil in the elderly J Hypertens 1998 16 (Suppl 2): 249

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Starnberg, Germany

    P Trenkwalder

Authors
  1. P Trenkwalder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Trenkwalder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trenkwalder, P. Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly. J Hum Hypertens 16 (Suppl 3), S71–S75 (2002). https://doi.org/10.1038/sj.jhh.1001443

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001443

Keywords

This article is cited by

Search

Advanced search

Quick links